



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_23_26

You asked:

I have a Freedom of Information request that I would like to raise.

Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?

Six (6).

Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months?

Five (5).

Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

Please see the information provided in the table below. Noting the following:

*Where the figures are less than 5, the exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

- **R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) = *Less than 5**
- **R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) = 0**
- **Pola-BR (polatuzumab vedotin with rituximab and bendamustine) = 0**
- **Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone) = 6**
- **R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate) = 0** (inpatient SACT commissioned to [Cardiff and Vale University Health Board \(CAVUHB\)](#) for further information, please contact them directly via the link provided).
- **R-IVAC (rituximab, ifosfamide, etoposide and cytarabine) = 0** (inpatient SACT commissioned to CAVUHB)

- **R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone) = *Less than 5**
- **(DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab) = 0** (inpatient SACT commissioned to CAVUHB)
- **R-GemOX (rituximab, gemcitabine and oxaliplatin) = 0**
- **Axicabtagene ciloleucel = 0** (CAR-T commissioned to CAVUHB)
- **Tisagenlecleucel = 0** (CAR-T commissioned to CAVUHB)
- **Epcoritamab = 0**
- **Loncastuximab tesirine = 0**
- **Glofitamab = 0**
- **Any other SACT: - CCEP = *Less than 5**
- **Stem cell transplant or bone marrow transplant (autologous or allogeneic) = 0** (commissioned to CAVUHB)

Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):

- **Axicabtagene ciloleucel (Yescarta) = 0** (CAR-T commissioned to CAVUHB)
- **Tisagenlecleucel = 0** (CAR-T commissioned to CAVUHB)
- **Pola-BR (polatuzumab vedotin with rituximab and bendamustine) = 0**
- **R-GemOX (rituximab, gemcitabine and oxaliplatin) = 0**
- **Stem cell transplant or bone marrow transplant (autologous or allogeneic) = 0** (commissioned to CAVUHB)
- **Glofitamab = 0**
- **Any other treatments: - CCEP = *Less than 5**

Q4. In the last 6 months, how many patients has the Trust treated for 3rd line Diffuse Large B Cell Lymphoma (DLBCL)?

Zero (0).

Q5. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:

- **CAR-T Therapy (E.g. Axicabtagene ciloleucel)**
- **Stem cell transplant or bone marrow transplant (autologous or allogeneic)**
- **Any other treatment**

*Less than 5. Please note, the referrals were part of a local pathway due to a local Service Level Agreement (SLA) and not a national pathway i.e. not a referral to a tertiary centre.